Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up

NCT01685931 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.

NCT NCT01685931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up
Lead sponsor
Xian-Janssen Pharmaceutical Ltd.
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2012
Completion date
December 31, 2014
Enrollment
617 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia